Comparison of SARS-CoV-2 Detection in Nasopharyngeal Swab and Saliva Samples from Patients Infected with Omicron Variant.
COVID-19 diagnosis
SARS-CoV-2
antiviral agents
monoclonal antibodies
saliva samples
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
02 Mar 2023
02 Mar 2023
Historique:
received:
15
02
2023
accepted:
24
02
2023
entrez:
11
3
2023
pubmed:
12
3
2023
medline:
15
3
2023
Statut:
epublish
Résumé
To compare the detection of the SARS-CoV-2 Omicron variant in nasopharyngeal-swab (NPS) and oral saliva samples. 255 samples were obtained from 85 Omicron-infected patients. SARS-CoV-2 load was measured in the NPS and saliva samples by using Simplexa™ COVID-19 direct and Alinity m SARS-CoV-2 AMP assays. Results obtained with the two diagnostic platforms showed very good inter-assay concordance (91.4 and 82.4% for saliva and NPS samples, respectively) and a significant correlation among cycle threshold (Ct) values. Both platforms revealed a highly significant correlation among Ct obtained in the two matrices. Although the median Ct value was lower in NPS than in saliva samples, the Ct drop was comparable in size for both types of samples after 7 days of antiviral treatment of the Omicron-infected patients. Our result demonstrates that the detection of the SARS-CoV-2 Omicron variant is not influenced by the type of sample used for PCR analysis, and that saliva can be used as an alternative specimen for detection and follow-up of Omicron-infected patients.
Identifiants
pubmed: 36902277
pii: ijms24054847
doi: 10.3390/ijms24054847
pmc: PMC10003189
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministero della Salute
ID : Programme CCM 2020 Ricerca Corrente - Linea 1 on emerging and re-emerging infections
Organisme : European Commission
ID : CoNVat, Grant agreement ID 101003544; KRONO, Grant agreement ID 101005075; Grant Number SHARP: 848096
Références
Am J Infect Control. 2021 Sep;49(9):1165-1176
pubmed: 33774101
J Clin Virol Plus. 2022 Aug;2(3):100090
pubmed: 35693461
EBioMedicine. 2022 Sep;83:104232
pubmed: 35988466
J Clin Virol. 2020 Jul;128:104416
pubmed: 32388470
J Infect. 2021 Jul;83(1):e8-e10
pubmed: 34023366
Lancet Respir Med. 2021 Jun;9(6):562-564
pubmed: 33887248
Emerg Infect Dis. 2021 Apr;27(4):1146-1150
pubmed: 33754989
Front Public Health. 2021 May 21;9:589564
pubmed: 34150692
Science. 2021 Nov 19;374(6570):995-999
pubmed: 34648303
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Microbiol Spectr. 2022 Dec 21;10(6):e0222922
pubmed: 36409097
J Clin Virol. 2022 Jul;152:105170
pubmed: 35525108
J Med Virol. 2022 Oct;94(10):4704-4711
pubmed: 35642439
Viruses. 2020 Oct 20;12(10):
pubmed: 33092065
Science. 2022 May 6;376(6593):eabn4947
pubmed: 35289632
Microbiol Spectr. 2022 Dec 21;10(6):e0252122
pubmed: 36318040
J Infect Chemother. 2021 Jul;27(7):1129-1130
pubmed: 33888419
J Clin Med. 2021 Apr 02;10(7):
pubmed: 33918294
JAMA Intern Med. 2021 Mar 1;181(3):353-360
pubmed: 33449069
Lancet Infect Dis. 2021 Oct;21(10):1354
pubmed: 34363772
Int J Infect Dis. 2022 Sep;122:401-404
pubmed: 35760381